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The revised paragraph is given here:
The cost-effectiveness analysis was carried out using a Markov model constructed in the decisionanalytic program package DATA (TreeAge Software Inc.). The model predicted costs and qualityadjusted life years (QALYs) over the remaining lifetime of the patients (limited to 110 years of age). The average follow-up time in SCOPE was 3.7 years. Patients in the candesartan group were therefore assumed to be treated with candesartan for a maximum of 4 years. Treatment cost, risk of nonfatal stroke, mortality during the first 4 years, cost of nonfatal stroke and utility reduction from nonfatal stroke were based on data collected in SCOPE. Epidemiological data were used to estimate mortality after the follow-up of the study. The analysis focused exclusively on the effects of candesartan-based antihypertensive treatment on the prevention of nonfatal stroke since there were no significant differences in other cardiovascular events. 
